Fee D - Search Results

1

Ordering multigene testing in polyneuropathy.

Fee D, Marques W Jr. Fee D, et al. Neurology. 2016 May 10;86(19):1752-3. doi: 10.1212/WNL.0000000000002663. Epub 2016 Apr 13. Neurology. 2016. PMID: 27164710 No abstract available.

2

Generation and propagation of the action potential.

Raghavan M, Fee D, Barkhaus PE. Raghavan M, et al. Among authors: fee d. Handb Clin Neurol. 2019;160:3-22. doi: 10.1016/B978-0-444-64032-1.00001-1. Handb Clin Neurol. 2019. PMID: 31277855 Review.

3

An autosomal dominant ataxia maps to 19q13: Allelic heterogeneity of SCA13 or novel locus?

Waters MF, Fee D, Figueroa KP, Nolte D, Müller U, Advincula J, Coon H, Evidente VG, Pulst SM. Waters MF, et al. Among authors: fee d. Neurology. 2005 Oct 11;65(7):1111-3. doi: 10.1212/01.wnl.0000177490.05162.41. Epub 2005 Aug 31. Neurology. 2005. PMID: 16135769

4

US data on children and youth caregivers in amyotrophic lateral sclerosis.

Kavanaugh MS, Cho CC, Howard M, Fee D, Barkhaus PE. Kavanaugh MS, et al. Among authors: fee d. Neurology. 2020 Apr 7;94(14):e1452-e1459. doi: 10.1212/WNL.0000000000009217. Epub 2020 Mar 18. Neurology. 2020. PMID: 32188763

5

Motor Neuron Generation from iPSCs from Identical Twins Discordant for Amyotrophic Lateral Sclerosis.

Seminary ER, Santarriaga S, Wheeler L, Mejaki M, Abrudan J, Demos W, Zimmermann MT, Urrutia RA, Fee D, Barkhaus PE, Ebert AD. Seminary ER, et al. Among authors: fee d. Cells. 2020 Feb 28;9(3):571. doi: 10.3390/cells9030571. Cells. 2020. PMID: 32121108 Free PMC article.

6

Skill, confidence and support: conceptual elements of a child/youth caregiver training program in amyotrophic lateral sclerosis - the YCare protocol.

Kavanaugh MS, Cho Y, Fee D, Barkhaus PE. Kavanaugh MS, et al. Among authors: fee d. Neurodegener Dis Manag. 2020 Aug;10(4):231-241. doi: 10.2217/nmt-2020-0004. Epub 2020 Aug 4. Neurodegener Dis Manag. 2020. PMID: 32749175

7

Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.

Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamäki M, Garratt C, Al-Chalabi A; REFALS investigators. Cudkowicz M, et al. Lancet Neurol. 2021 Oct;20(10):821-831. doi: 10.1016/S1474-4422(21)00242-8. Lancet Neurol. 2021. PMID: 34536404

8

Phenotypic variability associated with Arg26Gln mutation in caveolin3.

Fee DB, So YT, Barraza C, Figueroa KP, Pulst SM. Fee DB, et al. Muscle Nerve. 2004 Sep;30(3):375-8. doi: 10.1002/mus.20092. Muscle Nerve. 2004. PMID: 15318349

9

Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes.

Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D, Mock AF, Evidente VG, Fee DB, Müller U, Dürr A, Brice A, Papazian DM, Pulst SM. Waters MF, et al. Among authors: fee db. Nat Genet. 2006 Apr;38(4):447-51. doi: 10.1038/ng1758. Epub 2006 Feb 26. Nat Genet. 2006. PMID: 16501573

10

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.

Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman AV, Yu H, Drake K, Andrews J, Shefner J, Chibnik LB, Vestrucci M, Cudkowicz ME; Healey ALS Platform Trial Study Group. Paganoni S, et al. Ann Neurol. 2022 Feb;91(2):165-175. doi: 10.1002/ana.26285. Epub 2022 Jan 10. Ann Neurol. 2022. PMID: 34935174 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

50 results

Search Page

Filters